Primary intracranial malignant melanomas: A case series with literature review
Lifeng Chen,Yang Yang,Dongmei Li,Bo Bu
DOI: https://doi.org/10.1097/md.0000000000040334
IF: 1.6
2024-11-06
Medicine
Abstract:Primary intracranial malignant melanoma (PIMM) is a rare malignancy, representing 0.07% of all cases of intracranial tumors. [ 1 ] In addition, it only accounts for ~1% of all melanoma cases. [ 2 ] According to their pathological behavior, PIMMs are classified into 2 types: the solitary type presents as a nodular mass, and the diffuse type infiltrates the pia mater and involves the subarachnoid space. [ 3 ] Due to the rarity of PIMMs and the lack of randomized studies, there is a high chance of misdiagnosis and limited knowledge regarding the type of therapeutic strategies effective against this disease. [ 1–6 ] Although the preoperative symptoms and imaging findings are similar to those of meningiomas or benign melanocytomas, PIMM has a variable prognosis. It is important to accurately diagnose and identify the exact extent of the tumor area. [ 5 ] Resection or biopsy combined with adjuvant treatment, including whole-brain RT (WBRT), stereotactic radiosurgery (SRS), chemotherapy, and/or immunotherapy, have all been recommended. [ 3 ] However, gross total resection has been reported to improve the outcomes of PIMMs. [ 3 ] The benefits of radiation therapy, chemotherapy, and immunotherapy for PIMM remain controversial, and the prognosis of this disease remains poor. [ 1–6 ] Therefore, in the present study, the clinical features, treatment modalities, and outcomes of patients with histologically proven PIMM were retrospectively reviewed and discussed.
medicine, general & internal